Essential Medicines · LP-002
Paracetamol Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-002Essential Medicines
- Generic identity
- ParacetamolTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-002
- Generic identity
- Paracetamol
- Presentation
- Tablet
- Catalogue strength
- 500 mg; 650 mg
- Catalogue pack
- Blister 10 x 10 tablets; bottle 100 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: paracetamol.
- Dosage form: tablet.
- Proposed strengths: 500 mg and 650 mg.
- General proposed packs: blister 10 × 10 tablets; bottle 100 tablets.
Layer 02 · Unresolved product-specific fields
- Immediate-, modified- or extended-release character for either strength.
- Whether either tablet is scored, divisible or crushable.
- Strength-to-pack mapping.
- Approved indication, dosing, storage, shelf life, registration and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 500 mg | Tablet | — | Blister/bottle options not mapped by strength | Release characteristics and divisibility are not supplied. |
| B | 650 mg | Tablet | — | Blister/bottle options not mapped by strength | 650 mg alone does not establish extended or modified release. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Paracetamol, also called acetaminophen, is an analgesic and antipyretic used for pain and fever in appropriate patients. It is distinct from anti-inflammatory medicines such as ibuprofen. Different oral and rectal presentations contain the same active ingredient, so exposure from all products must be considered together. This educational profile describes the medicine generally; the approved indication, age range and instructions for a Luang Pharma presentation require its own authorized labeling.
Clinical context and therapeutic role
The clinical task is to relieve discomfort while recognizing the cause of persistent or severe symptoms. Fever with breathing difficulty, marked lethargy, dehydration, or other concerning features needs medical assessment rather than repeated symptom suppression. Children require an age-appropriate presentation and a professional or label-based plan. Combination cold, flu and pain products may also contain paracetamol, which is why a complete medication history is particularly important.
Selected safety context
Excess paracetamol can cause severe liver injury, sometimes before a person feels unwell. Suspected overdose requires urgent medical or poison-service advice even if there are no symptoms. Liver disease, heavy alcohol use, malnutrition and other medicines can affect safety. Avoid unintentionally combining several paracetamol-containing products. Serious allergy and severe skin reactions are possible. Persistent pain or fever should be reassessed; changing between oral and rectal forms does not avoid the overdose risk.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
Professional review should verify the precise presentation, intended population and current local authorization, then ensure that symptom treatment does not delay diagnosis or urgent care. The supplied label remains the source for patient instructions.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and formulation.
Approved label identifying release characteristics and administration instructions.
Pack/SKU matrix.
Registration/market-status evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B06 checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: Paracetamol for adultsArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling or evidence of equivalence. |
| NHS: Paracetamol for childrenArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling or evidence of equivalence. |
| MedlinePlus: Acetaminophen rectalArchived source classification: NLM-hosted medicine monograph | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-002.
Professional enquiries
Request product-specific evidence for LP-002.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.